The Horizon 2020 experts in GAEU proved to be very efficient and professional in their work and had great commitment and interest in our project which resulted in a grant of EUR 4.25 million.

The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. Cellink was granted € 2.5M from the SME Instrument HORIZON 2020, phase 2.   “Collaborating with GAEU has been…

In the application process, GAEU Consulting has proven itself to be a first class life science advisor, showing excellent understanding of our candidate drug and forces driving commercialization of medicinal products.

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. CombiGene was granted €3.3 million from the SME Instrument HORIZON 2020, phase 2.   “GAEU has in a significant way contributed to the successful outcome of our Horizon 2020-application. Both their experience…

At SenzaGen, we have strong ambitions to grow and enable animal-free, cell-based systems to assess hazards and potency of industrial compounds.

Corline, founded in 1991, develops, manufactures and markets heparin based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Coreline was granted € 2.3M from the SME Instrument HORIZON 2020, phase 2.   “This is absolutely fantastic for Corline! This grant is one of the highest allocations awarded…